1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,323 | 0,353 | 10:01 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07:26 | Cantargia Publishes Interim Report for January to September 2025 | 132 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 19, 2025 / Cantargia AB (publ) ("Cantargia") (STO:CANTA) issued its interim report for the period January until September 2025. The report is now available on the... ► Artikel lesen | |
| 12.11. | Cantargia Presents Nomination Committee Ahead of 2026 AGM | 192 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 12, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) (Nasdaq Stockholm:CANTA) today provided notification that the Nomination Committee (NC) has been appointed... ► Artikel lesen | |
| 05.11. | Invitation to the Presentation of Cantargia's Interim Report January-September 2025 | 187 | ACCESS Newswire | LUND, SE / ACCESS Newswire / November 5, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) (Nasdaq Stockholm:CANTA) will publish the company's interim report for the first nine months of 2025 on Wednesday... ► Artikel lesen | |
| 23.10. | Cantargia to Participate in Upcoming Conferences | 199 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 23, 2025 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA)(STO:CANTA) today announced that management will participate in the following investor conferences.Stifel... ► Artikel lesen | |
| 02.10. | Cantargia Appoints Dr. Wolfram Dempke As Chief Medical Officer | 203 | ACCESS Newswire | LUND, SE / ACCESS Newswire / October 2, 2025 / Cantargia (STO:CANTA) - Cantargia AB (publ) (Nasdaq Stockholm: CANTA) today announced the appointment of Wolfram Dempke, MD, PhD, MBA as Chief Medical... ► Artikel lesen | |
| 01.10. | Cantargia Presents Data at an AACR Conference Strengthening IL1RAP as a Targetable Hallmark in PDAC | 323 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 30, 2025 / Cantargia (STO:CANTA)High IL1RAP protein expression on tumor cells is linked to poor survival in PDAC patients treated with chemotherapy, while this... ► Artikel lesen | |
| 11.09. | Cantargia Closes the Acquisition of CAN10 by Otsuka | 320 | ACCESS Newswire | LUND, SE / ACCESS Newswire / September 11, 2025 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) today announced that Cantargia and its partner Otsuka Pharmaceutical Co., Ltd. (Otsuka) have closed Otsuka's... ► Artikel lesen | |
| CANTARGIA Aktie jetzt für 0€ handeln | |||||
| 29.08. | Cantargia im Q2 2025: Otsuka-Deal bringt 33 Mio. USD Sofortzahlung bei durchwachsenen klinischen Ergebnissen | 6 | Investing.com Deutsch | ||
| 29.08. | Cantargia Q2 2025 slides: Otsuka deal brings $33M upfront amid mixed clinical results | 2 | Investing.com | ||
| 27.08. | Cantargia Granted Important US Patent for Nadunolimab | 243 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 27, 2025 / Cantargia AB (Publ), Nasdaq Stockholm:CANTA, (Cantargia) today announced that the United States Patent and Trademark Office (USPTO) has granted the patent... ► Artikel lesen | |
| 21.08. | Cantargia: Aktie gibt trotz 630-Mio.-Dollar-Deal mit Otsuka nach | 5 | Investing.com Deutsch | ||
| 21.08. | Cantargia Publishes Half-Year Report 2025 | 344 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 21, 2025 / Cantargia AB (publ) [Nasdaq Stockholm:CANTA] (Cantargia) today issued the interim report for January to June 2025."I started my tenure as interim CEO with... ► Artikel lesen | |
| 18.08. | Cantargia Appoints Dr Hilde Steineger as Chief Executive Officer | 368 | ACCESS Newswire | Dr Steineger's appointment will be effective from September 1.She brings extensive experience as a biotech executive, with a proven track record spanning financial analysis, venture capital, and business... ► Artikel lesen | |
| 12.08. | Invitation to the Presentation of Cantargia's H1 2025 Report | 276 | ACCESS Newswire | LUND, SE / ACCESS Newswire / August 12, 2025 / Cantargia (Cantargia AB (publ); Nasdaq Stockholm:CANTA) will publish the company's interim report for the first six months of 2025 on Thursday, August... ► Artikel lesen | |
| 17.07. | Cantargia Announces Preliminary Topline Efficacy Results From the Phase 2 TRIFOUR Trial of Nadunolimab in Advanced Triple-Negative Breast Cancer | 448 | ACCESS Newswire | LUND, SWEDEN / ACCESS Newswire / July 17, 2025 / Cantargia (STO:CANTA)Nadunolimab added to carboplatin and gemcitabine (GC) did not impact the safety profile of the chemotherapy and was well tolerated... ► Artikel lesen | |
| 16.07. | Cantargia Announces Publication of Clinical Data Showing Benefit of Nadunolimab Combination Therapy in Advanced Lung Cancer | 359 | ACCESS Newswire | LUND, SE / ACCESS Newswire / July 16, 2025 / Cantargia (STO:CANTA)Promising efficacy data with median PFS of 7.2 months (95%CI 5.6-9.2), median OS of 13.7 months (95%CI 11.1-18.3), and 1-year survival... ► Artikel lesen | |
| 15.07. | Otsuka to acquire Cantargia's CAN10 for autoimmune diseases | 4 | Pharmaceutical Technology | ||
| 15.07. | Cantargia Announces the Acquisition of its CAN10 IL1RAP Immunology Program by Otsuka Pharmaceutical | 470 | ACCESS Newswire | Cantargia receives an upfront cash payment of USD 33 million.Cantargia is eligible to receive up to USD 580 million in development, regulatory and commercial milestone payments plus earn-out payments... ► Artikel lesen | |
| 17.06. | Cantargia Signs SEK 50 Million Financing Facility Agreement, Extending Cash Runway Into 2026 and Providing Operating Flexibility to Drive Strategic Plans | 352 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 17, 2025 / Cantargia (STO:CANTA) - Cantargia (Cantargia AB (publ); Nasdaq Stockholm: CANTA) today announced that it has entered into a loan agreement of SEK 50 million... ► Artikel lesen | |
| 17.06. | Cantargia Q1 2025 slides: CAN10 advances amid funding challenges | 3 | Investing.com |
1 2 3 Weiter >>
55 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 89,00 | +0,51 % | Frank Fischer (Shareholder Value): BioNTech & Co. mit neuem Schwung und Momentum | 10.11.2025 - Die Berichtssaison für das 3. Quartal ist in vollem Gange. US-Big-Techs wie Microsoft und Amazon haben starke Zahlen vorgelegt. Europa liegt über den Erwartungen. Und: Im Biotech-Bereich... ► Artikel lesen | |
| EVOTEC | 5,250 | +0,92 % | Evotec: Meilenstein von Pharma-Giganten - Aktie sendet Lebenszeichen | Gute Nachrichten von Evotec. Der Hamburger Wirkstoffforscher ist wieder einen Schritt weiter in der Zusammenarbeit mit dem amerikanischen Pharma-Riesen Bristol Myers Squibb. Evotec erhält in diesem... ► Artikel lesen | |
| QIAGEN | 38,395 | +1,70 % | AIM WINNERS & LOSERS: CelLBxHealth rises on Qiagen deal | ||
| REGENERON PHARMACEUTICALS | 628,60 | +0,32 % | Regeneron pledges $2B to convert former magazine factory into drug plant: NY governor | ||
| BRAIN BIOTECH | 2,900 | +2,11 % | EQS-PVR: BRAIN Biotech AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: BRAIN Biotech AG
BRAIN Biotech AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
20.10.2025 / 15:38 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | ||
| CARDIOL THERAPEUTICS | 0,862 | -2,60 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040 | Once issued, this new U.S. patent covers the use of CardiolRx and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual property... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 1,340 | +6,35 % | Burcon NutraScience Corporation: Burcon Announces Fiscal 2026 Second Quarter Results | Vancouver, British Columbia--(Newsfile Corp. - November 12, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
| CSL | 100,00 | +0,25 % | CSL to pour $2.3 billion into US investments in attempt to dodge Trump's tariffs | ||
| MANNKIND | 4,381 | +0,34 % | MannKind: Stiller Gewinner im Kampf um die Lunge? | Nach einer Reihe operativer Fortschritte und der Übernahme von scPharmaceuticals richtet sich bei Aktionären der MannKind Corporation der Blick in die Zukunft. Die fundamentale Basis scheint geschaffen.... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 10,035 | -1,18 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Third Quarter 2025 Financial Results and Business Highlights | Recent Investor Day highlighted how AXPAXLI is positioned to redefine retina based on potential superiority label, market expansion, and immediate adoptability Announced today that SOL-R achieved... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 1,400 | -1,69 % | Oxford Nanopore Tech - Share Incentive Plan - Director/PDMR Shareholding | ||
| ADAPTIMMUNE THERAPEUTICS | 0,052 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| CODEXIS | 1,410 | -0,77 % | Codexis, Inc.: Codexis Reports Third Quarter 2025 Financial Results | Announces signing of $37.8m Supply Assurance Agreement with Merck Organizational changes streamline company and reduce operational expenses Cash runway extended through 2027 REDWOOD CITY, Calif.,... ► Artikel lesen | |
| CORMEDIX | 8,500 | -2,30 % | CorMedix, Inc.: CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance | - Q3 2025 Net Revenue of $104.3 million; Pro Forma Net Revenue of $130.8 million - Q3 2025 Net Income of $108.6 million; Adjusted EBITDA of $71.9 million - FY 2025 Pro Forma Net Revenue Guidance Raised... ► Artikel lesen |
CANTARGIA AB gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,282 Euro und damit -0,71 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CANTARGIA AB finden Sie auf Wallstreet Online.